Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer

Gynecol Oncol. 2019 Jun;153(3):471-478. doi: 10.1016/j.ygyno.2019.03.247. Epub 2019 Mar 29.

Abstract

Polymerase-epsilon (POLE)-mutated carcinomas are a rare, but well-known subtype of endometrial cancer. While typically associated with good prognosis, recurrences are documented. Here we present a case of recurrent POLE-mutated endometrial cancer, discuss pathologic features, current methods of molecular classification, and explore therapeutic implications for the POLE-mutation phenotype.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / diagnosis
  • Adenocarcinoma / genetics*
  • Adenocarcinoma / secondary
  • Adenocarcinoma / therapy*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols
  • Carboplatin / administration & dosage
  • DNA Polymerase II / genetics*
  • Endometrial Neoplasms / genetics*
  • Endometrial Neoplasms / pathology
  • Endometrial Neoplasms / therapy
  • Female
  • Humans
  • Middle Aged
  • Mutation
  • Omentum / surgery
  • Paclitaxel / administration & dosage
  • Pancreatic Neoplasms / diagnosis
  • Pancreatic Neoplasms / secondary
  • Pancreatic Neoplasms / therapy*
  • Poly-ADP-Ribose Binding Proteins / genetics*
  • Stomach Neoplasms / diagnosis
  • Stomach Neoplasms / genetics
  • Stomach Neoplasms / secondary
  • Stomach Neoplasms / therapy*

Substances

  • Antibodies, Monoclonal, Humanized
  • Poly-ADP-Ribose Binding Proteins
  • Carboplatin
  • pembrolizumab
  • DNA Polymerase II
  • POLE protein, human
  • Paclitaxel